Chinese dealmaking: SARI nabs Italy’s NMS Group for $362M; Inovio retools deal with ApolloBio
Two biopharma deals involving Chinese companies were announced during the holidays, marking the beginning of what we expect will be a booming year for dealmaking …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.